Report

reporttype1Version of Safety Report ID2receivedateformat102transmissiondateformat102fulfillexpeditecriteria2Safety Report ID10068747serious1Date Last Updated12/03/2015receiptdateformat102companynumbUS-ABBVIE-14P-163-1220726-00occurcountryUSduplicate1Date Received09/04/2014seriousnesshospitalization1transmissiondate20/07/2015primarysourcecountryUS

Primary Source

reportercountryUSqualification5

Patient

Onset Age8Unit of Onset AgeyearsWeight108.51SexMale

Reaction

1)

reactionmeddraversionpt18.0ReactionHepatic failureOutcomeNot recovered/not resolved

2)

reactionmeddraversionpt18.0ReactionMuscle spasmsOutcomeNot recovered/not resolved

3)

reactionmeddraversionpt18.0ReactionMood alteredOutcomeNot recovered/not resolved

4)

reactionmeddraversionpt18.0ReactionMental disorderOutcomeUnknown

5)

reactionmeddraversionpt18.0ReactionDrug dependenceOutcomeUnknown

6)

reactionmeddraversionpt18.0ReactionAnxietyOutcomeNot recovered/not resolved

7)

reactionmeddraversionpt18.0ReactionInfertility maleOutcomeNot recovered/not resolved

8)

reactionmeddraversionpt18.0ReactionPurine metabolism disorderOutcomeUnknown

9)

reactionmeddraversionpt18.0ReactionSperm concentration decreasedOutcomeNot recovered/not resolved

10)

reactionmeddraversionpt18.0ReactionAlanine aminotransferase abnormalOutcomeNot recovered/not resolved

11)

reactionmeddraversionpt18.0ReactionSpermatozoa progressive motility decreasedOutcomeNot recovered/not resolved

12)

reactionmeddraversionpt18.0ReactionDepressionOutcomeUnknown

13)

reactionmeddraversionpt18.0ReactionRashOutcomeNot recovered/not resolved

14)

reactionmeddraversionpt18.0ReactionHallucinationOutcomeRecovered/resolved

15)

reactionmeddraversionpt18.0ReactionIncreased appetiteOutcomeRecovered/resolved

16)

reactionmeddraversionpt18.0ReactionWeight increasedOutcomeRecovered/resolved

17)

reactionmeddraversionpt18.0ReactionDermatitisOutcomeNot recovered/not resolved

18)

reactionmeddraversionpt18.0ReactionAspartate aminotransferase abnormalOutcomeNot recovered/not resolved

19)

reactionmeddraversionpt18.0ReactionInsomniaOutcomeUnknown

20)

reactionmeddraversionpt18.0ReactionAbdominal pain upperOutcomeRecovered/resolved

21)

reactionmeddraversionpt18.0ReactionBreast disorder maleOutcomeUnknown

22)

reactionmeddraversionpt18.0ReactionConfusional stateOutcomeRecovered/resolved

23)

reactionmeddraversionpt18.0ReactionGait disturbanceOutcomeNot recovered/not resolved

24)

reactionmeddraversionpt18.0ReactionAbdominal discomfortOutcomeRecovered/resolved

25)

reactionmeddraversionpt18.0ReactionCrohn^s diseaseOutcomeNot recovered/not resolved

Drug

1)

drugcharacterization2medicinalproductZOLOFTdrugindicationANXIETY

activesubstance

activesubstancenameSERTRALINE HYDROCHLORIDE

openFDA Info on Medication

Application NumberNDA020990, NDA019839Brand NameZOLOFTGeneric NameSERTRALINE HYDROCHLORIDEManufacturersRoerigproduct_ndc0049-0050, 0049-4960, 0049-4900, 0049-4910Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsSERTRALINE HYDROCHLORIDERXCUI208149, 208161, 212233, 312938, 312940, 312941, 861064, 861066spl_id665a145d-44fb-4fef-a3c1-2aac26e0715cspl_set_idfe9e8b7d-61ea-409d-84aa-3ebd79a046b5Package NDC 0049-4960-30, 0049-4960-50, 0049-4900-30, 0049-4900-66, 0049-4900-73, 0049-4900- ... UNIIUTI8907Y6X

2)

drugcharacterization1medicinalproductDEPAKOTEdrugbatchnumb00074-6214-13drugauthorizationnumb018723drugdosageformTABLETdrugindicationPRODUCT USED FOR UNKNOWN INDICATIONdrugstartdateformat610drugstartdate/10/1997drugenddateformat610drugenddate/03/1998

activesubstance

activesubstancenameDIVALPROEX SODIUM

openFDA Info on Medication

Application NumberNDA021168, NDA018723, NDA019680Brand NameDEPAKOTE ER, DEPAKOTE, DEPAKOTE SPRINKLESGeneric NameDIVALPROEX SODIUMManufacturersAbbVie Inc.product_ndc0074-3826, 0074-7126, 0074-6212, 0074-6214, 0074-6215, 0074-6114Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsDIVALPROEX SODIUMRXCUI 1099563, 1099565, 1099569, 1099571, 1099625, 1099626, 1099678, 1099679, 1099870, ... spl_id bda1168f-9cb8-cfc6-ccea-f576f45e25a6, 3c11ce81-9241-56ec-0783-7843408c10b9, f636 ... spl_set_id 0dc024ce-efc8-4690-7cb5-639c728fccac, 08a65cf4-7749-4ceb-6895-8f4805e2b01f, 4619 ... Package NDC 0074-3826-13, 0074-3826-11, 0074-7126-13, 0074-7126-53, 0074-7126-11, 0074-7126- ... UNII644VL95AO6

3)

drugcharacterization2medicinalproductREMICADEdrugindicationCROHN^S DISEASE

activesubstance

activesubstancenameINFLIXIMAB

openFDA Info on Medication

Application NumberBLA103772Brand NameREMICADEGeneric NameINFLIXIMABManufacturersJanssen Biotech, Inc.product_ndc57894-030Product TypeHUMAN PRESCRIPTION DRUGRouteINTRAVENOUSActive IngredientsINFLIXIMABRXCUI213361, 310994spl_idba599d34-1a9a-47db-8414-8e7cfcb5d49dspl_set_ida0a046c1-056d-45a9-bfd9-13b47c24f257Package NDC57894-030-01NUIN0000175610, N0000175451Established Pharmacologic ClassTumor Necrosis Factor Blocker [EPC]Mechanism of ActionTumor Necrosis Factor Receptor Blocking Activity [MoA]UNIIB72HH48FLU

summary

narrativeincludeclinicalCASE EVENT DATE: 199710

Report Duplicate

duplicatesourceABBVIEduplicatenumbUS-ABBVIE-14P-163-1220726-00

Receiver

receivertype6receiverorganizationFDA

Sender

sendertype2senderorganizationFDA-Public Use

Adverse Event Report

Report

Primary Source

Patient

Reaction

1)

2)

3)

4)

5)

6)

7)

8)

9)

10)

11)

12)

13)

14)

15)

16)

17)

18)

19)

20)

21)

22)

23)

24)

25)

Drug

1)

activesubstance

openFDA Info on Medication

2)

activesubstance

openFDA Info on Medication

3)

activesubstance

openFDA Info on Medication

summary

Report Duplicate

Receiver

Sender

Media

Newsletter

Follow us

Connect with us